Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: 22nd European Society for Animal Cell Technology (ESACT) Meeting on Cell Based Technologies

Open Access Meeting abstract

High-capacity assay to quantify the clonal heterogeneity in potency of mesenchymal stem cells

Kim C O’Connor1*, Katie C Russell1, Donald G Phinney2, Michelle R Lacey1, Bonnie L Barrilleaux1 and Kristin E Meyertholen1

Author affiliations

1 Department of Chemical and Biomolecular Engineering, Tulane University, New Orleans, LA 70118, USA

2 Scripps Research Institute, Jupiter, FL, 33458, USA

For all author emails, please log on.

Citation and License

BMC Proceedings 2011, 5(Suppl 8):O14  doi:10.1186/1753-6561-5-S8-O14

The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1753-6561/5/S8/O14


Published:22 November 2011

© 2011 O’Connor et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background

The regenerative capacity of mesenchymal stem cells (MSCs) is contingent on their content of multipotent progenitors [1]. Despite its importance to the efficacy of MSC therapies, the clonal heterogeneity of MSCs remains poorly defined. To address this deficiency, the current study presents a novel high-capacity assay to quantify the clonal heterogeneity in MSC potency and demonstrates its utility to resolve regenerative properties as a function of potency. Human bone marrow was the source of MSCs in this study. The versatility and accessibility of marrow-derived MSCs make them a standard for many therapeutic applications.

Materials and methods

Primary MSCs were harvested from the iliac crest bone marrow of healthy adult volunteers and cultured as previously described [2]. The in vitro assay developed for this study utilizes a 96-well format to (1) clone fluorescent MSCs stained with CellTracker Green by limiting dilution, (2) generate matched clonal colonies, (3) differentiate 3 matched colonies per clone to quantify trilineage potential to exhibit adipo-, chondro- and osteogenesis as a measure of potency, and (4) cryopreserve the 4th matched colony of each clone in situ in an undifferentiated state for future use. Clones of known potency were evaluated for their colony-forming efficiency as a measure of proliferation potential [3]. Expression of the heterotypic cell adhesion molecule CD146 on the surface of MSC clones was measured with flow cytometry.

Results

All eight categories of trilineage potential were detected in human marrow MSCs. Multipotent MSCs had a higher proliferation potential than lineage-committed MSCs. Tripotent clones formed colonies with a median efficiency of 50%, as compared with 14% and 1% for bi- and unipotent clones, respectively (p < 0.01). Likewise, colonies that formed from tripotent clones had the largest median diameter. CD146 may be a biomarker of MSC potency. Histograms of fluorescence intensity from pooled tripotent clones labeled with anti-CD146 antibody shifted to higher CD146 expression relative to the parent MSC preparation from which the clones were generated; whereas, the histograms for parent MSCs and their unipotent progeny were similar. In particular, the mean fluorescence intensity of tripotent clones was nearly twice the value for the parent and unipotent MSCs (p < 0.05).

Conclusions

The research presented here addresses a basic deficiency in stem cell technology by developing a quantitative and high-capacity assay to characterize the clonal heterogeneity of MSC potency. The data suggest a complex hierarchy of lineage commitment in which proliferation potential and CD146 expression diminish with loss of potency. The capacity of multipotent MSCs for ex vivo expansion and their differential expression of a potential potency marker will facilitate rapid production of efficacious MSC therapies with consistent progenitor content. The assay has numerous basic research and clinical applications given the importance of heterogeneity to the therapeutic potential of MSCs.

Acknowledgements

We thank Alan Tucker for his assistance with flow cytometry, Dina Gaupp for preparing samples for histology, and Prof. Darwin Prockop for his helpful conversations and suggestions about this project. This research was sponsored by grants to Prof. O’Connor from the National Institutes of Health (R03EB007281) and National Science Foundation (BES0514242).

References

  1. Barrilleaux BL, Phinney DG, Prockop DJ, O’Connor KC: Ex vivo engineering of living tissue with adult stem cells.

    Tissue Eng 2006, 12:3007-3019. PubMed Abstract | Publisher Full Text OpenURL

  2. Barrilleaux BL, Phinney DG, Fischer-Valuck BW, Russell KC, Wang G, Prockop DJ, O’Connor KC: Small-molecule antagonist of macrophage migration inhibitory factor enhances migratory response of mesenchymal stem cells to bronchial epithelial cells.

    Tissue Eng Part A 2009, 15:2335-2346. PubMed Abstract | Publisher Full Text OpenURL

  3. Russell KC, Lacey MR, Gilliam JK, Tucker HA, Phinney DG, O’Connor KC: Clonal analysis of proliferation potential of human bone marrow mesenchymal stem cells as a function of potency.

    Biotechnol Bioeng 2011, 108:2716-2726.

    doi:10.1002/bit.23193

    PubMed Abstract | Publisher Full Text OpenURL